Amonkar Mayur M, Abderhalden Lauren A, Fox Grace E, Frederickson Andrew M, Grira Torkia, Gozman Alexander, Malhotra Usha, Malbecq William, Akers Katherine G
Merck & Co., Inc., Rahway, NJ 07065, USA.
MSD, 8058, Zurich, Switzerland.
Future Oncol. 2024 Apr;20(13):863-876. doi: 10.2217/fon-2023-0006. Epub 2024 Feb 14.
A systematic review and meta-analysis were performed to evaluate the efficacy of treatments for previously treated advanced biliary tract cancer (BTC) patients. Databases were searched for studies evaluating treatments for advanced (unresectable and/or metastatic) BTC patients who progressed on prior therapy. Pooled estimates of objective response rate (ORR), median overall survival (OS) and median progression-free survival (PFS) were calculated using random effects meta-analysis. Across 31 studies evaluating chemotherapy or targeted treatment regimens in an unselected advanced BTC patient population, pooled ORR was 6.9%, median OS was 6.6 months and median PFS was 3.2 months. The efficacy of conventional treatments for previously treated advanced BTC patients is poor and could be improved by novel therapies.
进行了一项系统评价和荟萃分析，以评估治疗既往接受过治疗的晚期胆管癌（BTC）患者的疗效。检索数据库以查找评估先前治疗进展的晚期（不可切除和/或转移性）BTC患者治疗方法的研究。使用随机效应荟萃分析计算客观缓解率（ORR）、中位总生存期（OS）和中位无进展生存期（PFS）的合并估计值。在31项评估未选择的晚期BTC患者群体中化疗或靶向治疗方案的研究中，合并ORR为6.9%，中位OS为6.6个月，中位PFS为3.2个月。既往接受过治疗的晚期BTC患者的传统治疗效果较差，新疗法可能会改善这种情况。
Zotero 插件